Clinical Trials Logo

Osteogenesis Imperfecta clinical trials

View clinical trials related to Osteogenesis Imperfecta.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06193642 Recruiting - Clinical trials for Osteogenesis Imperfecta

Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data

4FRAILTY
Start date: January 20, 2023
Phase: N/A
Study type: Interventional

interventional pilot study with the enrollment of patients affected by Osteogenesis Imperfecta

NCT ID: NCT06086613 Recruiting - Clinical trials for Osteogenesis Imperfecta

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Start date: October 3, 2023
Phase: Phase 1
Study type: Interventional

To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.

NCT ID: NCT06065111 Recruiting - Clinical trials for Osteogenesis Imperfecta

Study of Osteogenesis Imperfecta Tendon

SOIT
Start date: September 13, 2023
Phase:
Study type: Observational

Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities. However, other tissues rich in type I collagen can also be affected, such as teeth or vessel walls. In the literature, several case reports describe tendon ruptures in OI patients, but no original study has really addressed this issue, which is likely to impact the quality of life through a reduction in mobility and pain. Recent work carried out by the investigators shows an alteration of the osteotendinous unit in the osteogenesis imperfecta mouse (oim), a validated model of the most severe form of OI. Consequently, the project aims to study the damage of tendon and ligament in patients suffering from osteogenesis imperfecta.

NCT ID: NCT06010134 Recruiting - Clinical trials for Osteogenesis Imperfecta

Osteogenesis Imperfecta and Balance

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. It results in bones that break easily. Its severity may be mild to severe. Other symptoms may include a blue tinge to the whites of the eye, short height, loose joints, hearing loss, breathing problems and problems with the teeth. Physiotherapy is aimed to strengthen muscles and improve motility in a gentle manner, while minimizing the risk of fracture, and the use of support cushions to improve posture.

NCT ID: NCT05972551 Recruiting - Clinical trials for Osteogenesis Imperfecta

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Start date: April 22, 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.

NCT ID: NCT05927389 Recruiting - Clinical trials for Osteogenesis Imperfecta

Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis Imperfecta

BONeMOVE
Start date: February 26, 2024
Phase: N/A
Study type: Interventional

This research study aims to evaluate the effect of a 6-month adapted physical activity program (APA) on the endurance capacities (evaluated as the maximum oxygen consumption [VO2 peak]) of children and adolescents with Osteogenesis Imperfecta.

NCT ID: NCT05878548 Recruiting - Clinical trials for Osteogenesis Imperfecta

Management of Combined Fracture Neck of Femur and Femoral Deformity in Osteogenesis Imperfecta Patient

OI
Start date: August 1, 2023
Phase: N/A
Study type: Interventional

O.I with NOF fixed by Wagner technique and telescoping nail

NCT ID: NCT05419960 Recruiting - Clinical trials for Osteogenesis Imperfecta

Audio-vestibular Evaluation of Children and Young Adults With Osteogenesis Imperfecta

AVOI
Start date: December 22, 2022
Phase:
Study type: Observational

The aim is to determine whether vestibular deficits are present in OI, then to establish whether a correlation exists between genetic type, severity of OI and audiovestibular phenotype. OI patients aged 12 to 20 years will undergo an audiometric, immittance, and vestibular assessment. When hearing loss is conductive or mixed or in cases where vestibular deficits are identified, a CT scan without injection will be performed. In case of sensorineural hearing loss or abnormal CT results, an MRI will be performed.

NCT ID: NCT05317637 Recruiting - Clinical trials for Osteogenesis Imperfecta

Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708

Start date: August 1, 2022
Phase:
Study type: Observational

Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.

NCT ID: NCT05231668 Recruiting - Clinical trials for Osteogenesis Imperfecta

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Start date: August 25, 2022
Phase: Phase 1
Study type: Interventional

SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be evaluated by dual-energy Xray absorptimetry (DXA) scan and a series of blood biomarkers will be monitored to document pharmacodynamic effects of the single dose of SAR439459.